[关键词]
[摘要]
目的 探究参麦注射液联合噻托溴铵治疗慢性阻塞性肺疾病的临床疗效。方法 选取2014年7月-2015年3月首都医科大学宣武医院收治的慢性阻塞性肺疾病患者68例,随机分为对照组(31例)和治疗组(37例)。对照组吸入噻托溴铵粉雾剂,18 μg/次,1次/d。治疗组在对照组的基础上静脉注射参麦注射液,100 mL/次,1次/d。两组患者连续治疗14 d。观察两组的临床疗效,比较两组的动脉血气指标、肺功能指标和复发的情况。结果 治疗后,对照组和治疗组的总有效率分别为74.19%、91.89%,两组比较差异有统计学意义(P<0.05)。治疗后,两组血氧分压(pO2)和血氧饱和度(SpO2)均显著升高,而二氧化碳分压(pCO2)显著下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组第1秒用力呼吸容积(FEV1)、用力肺活量(FVC)和FEV1/FVC均明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标的升高程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。对照组和治疗组的复发率分别为38.71%、10.81%,两组比较差异有统计学意义(P<0.05)。结论 参麦注射液联合噻托溴铵治疗慢性阻塞性肺疾病具有较好的临床疗效,可明显改善肺功能,安全性好,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To explore the clinical effect of Shenmai Injection combined with tiotropium bromide in treatment of chronic obstructive pulmonary disease. Methods Patients (68 cases) with chronic obstructive pulmonary disease in Xuanwu Hospital Capital Medical University from July 2014 to March 2015 were randomly divided into control group (31 cases) and treatment group (37 cases). Patients in the control group were inhalation administered with Tiotropium Bromide Powder for inhalation, 18 μg/time, once daily. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 100 mL/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and arterial blood gas indexes, lung function indexes, and recurrence in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.19% and 91.89%, respectively, and there was difference between two groups (P<0.05). After treatment, pO2 and SpO2 in two groups were significantly increased, but pCO2 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, FEV1, FVC, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). The recurrence rates in the control and treatment groups were 38.71% and 10.81%, respectively, and there was difference between two groups (P<0.05). Conclusion Shenmai Injection combined with tiotropium bromide has clinical curative effect in treatment of chronic obstructive pulmonary disease, and can significantly improve lung function, with good safety,which has a certain clinical application value.
[中图分类号]
[基金项目]